Supportive care measures

DRUG10 trials

Sponsors

Merck Sharp & Dohme LLC, Hend Mahmoud Abdelghany, The First Affiliated Hospital with Nanjing Medical University, National Taiwan University Hospital

Conditions

37 or More Completed Weeks of GestationAdjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) At High Risk of Recurrence After Curative Resection or AblationBiliary Tract CancerColorectal CancerEsophageal Squamous Cell CarcinomaFirst BirthGastroesophageal CancerHeart Failure

Phase 1

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

RecruitingNCT05319730

Merck Sharp & Dohme LLCEsophageal Squamous Cell Carcinoma

Start: 2023-05-16End: 2029-04-10Target: 230Updated: 2026-03-20

Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)

Active, not recruitingNCT06049212

Merck Sharp & Dohme LLCNon-small Cell Lung Cancer, Programmed Cell Death 1 Ligand 1(PDL1, PD-L1), Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2) +2

Start: 2023-10-26End: 2027-01-29Target: 30Updated: 2025-12-19

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

RecruitingNCT06428409

Merck Sharp & Dohme LLCBiliary Tract Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma

Start: 2024-06-20End: 2029-10-16Target: 220Updated: 2026-01-22

A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

Active, not recruitingNCT06483334

Merck Sharp & Dohme LLCLocally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma

Start: 2024-07-17End: 2028-03-31Target: 38Updated: 2026-02-18

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

RecruitingNCT06637423

Merck Sharp & Dohme LLCNon-Muscle Invasive Bladder Cancer

Start: 2024-12-20End: 2028-07-31Target: 32Updated: 2026-02-19

Phase 2

Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After Surgery

RecruitingNCT06762782

The First Affiliated Hospital with Nanjing Medical UniversityAdjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) At High Risk of Recurrence After Curative Resection or Ablation, Hepatocellular Carcinoma (HCC)

Start: 2025-02-28End: 2027-10-31Target: 276Updated: 2025-01-08

Phase 3

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

RecruitingNCT06170788

Merck Sharp & Dohme LLCNon-small Cell Lung Cancer (NSCLC)

Start: 2023-12-15End: 2030-05-27Target: 614Updated: 2026-04-02

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

Active, not recruitingNCT06356311

Merck Sharp & Dohme LLCGastroesophageal Cancer

Start: 2024-05-03End: 2027-05-06Target: 450Updated: 2026-02-27

Unknown Phase

Comparative Study Between Using WHO Labour Care Guide & Modified WHO Partograph

CompletedNCT06537089

Hend Mahmoud Abdelghany37 or More Completed Weeks of Gestation, First Birth, Labor Onset and Length Abnormalities

Start: 2024-08-01End: 2025-12-31Updated: 2026-02-23

Comprehensive Management for Terminal Heart Failure Program:

Not yet recruitingNCT06892652

National Taiwan University HospitalHeart Failure

Start: 2025-04-30End: 2027-05-31Target: 40Updated: 2025-03-27

Related Papers

Intravesical sacituzumab tirumotecan in participants with intermediate-risk non–muscle-invasive bladder cancer: The phase 1/2 TroFuse-027 study.

Journal of Clinical Oncology2025-05-28

Phase 1/2 study of the trophoblast cell surface antigen 2 (TROP2) antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) as monotherapy or combination therapy in gastrointestinal cancers: LIGHTBEAM-02A.

Journal of Clinical Oncology2025-01-27

Sacituzumab tirumotecan (SKB264/MK-2870) in combination with KL-A167 (anti-PD-L1) as first-line treatment for patients with advanced NSCLC from the phase II OptiTROP-Lung01 study.

Journal of Clinical Oncology2024-06-0117 citations